TJP1 and breast carcinoma: revealed that transfer of breast cancer-secreted miR-105 to endothelial cells mediated by EVs efficiently disrupted the vascular permeability by inhibiting the tight junction protein ZO-1, which facilitates breast cancer intravasation in primary tumor sites and extravasation at metastatic sites.